AstraZeneca has announced new clinical trial data that demonstrates the effectiveness of its drug Lynparza in the treatment of specific forms of breast cancer.
Data from the phase III OLYMPIAD trial highlighted the performance of Lynparza tablets compared to a standard-of-care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
“AstraZeneca's Lynparza has demonstrated its effectiveness in the treatment of BRCA-mutated metastatic breast cancer.“
The findings showed that those treated with Lynparza experienced a statistically significant and clinically meaningful improvement in progression-free survival compared with those who received capecitabine, vinorelbine or eribulin chemotherapy.
The safety profile of AstraZeneca's drug was also shown to be consistent with previous studies. Based on these findings, the company will work to secure regulatory approval for Lynparza in this indication.
Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "This is highly encouraging for the development of our broad portfolio, which aims to treat multiple cancers by targeting DNA damage response pathways."
The study data represents the first positive phase III data to be recorded for a PARP inhibitor beyond ovarian cancer.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical